# Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia

> **NCT06629376** · PHASE1 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 60 (estimated)

## Conditions studied

- Gout
- Hyperuricemia

## Interventions

- **DRUG:** Pegylated Recombinant Candida Utilis Uricase for Injection

## Key facts

- **NCT ID:** NCT06629376
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-08-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06629376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06629376, "Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06629376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*